Generation of novel peptide-MHC antibody therapies to combat seasonal and pandemic potential influenza virus (Old ID 28968)
Role
Principal Investigator
Description
Influenza pandemics have caused significant morbidity and mortality throughout history. The 1918 influenza pandemic resulted in 25-50 million deaths globally. Myrio Therapeutics is a Melbourne-based company leading the development of antibodies directed to peptide-MHC (pMHC) targets. Myrio’s competitive edge is provided by a patented Retained Display (ReD) discovery platform allowing rapid isolation of high affinity human single chain antibodies, which are readily converted into different therapeutic formats. Myrio has identified several first-in-class antibodies against highly conserved influenza virus peptides presented on common human leukocyte antigens (HLAs) for further testing in vitro and in vivo in mice.
Date
27 Mar 2023 - 31 Dec 2024
Project Type
GRANT
Keywords
Influenza virus;Antibody-based therapies;Major Histocompatibility Complex;Influenza pandemic preparedness
Funding Body
CUREator
Amount
138920
Project Team
N/A